These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18842236)

  • 1. [First antiretroviral therapy regimen in HIV-infected patients. Durability and factors associated with therapy changes].
    de la Torre J; Santos J; Perea-Milla E; Pérez I; Moreno F; Palacios R; Santamaría S; Del Arco A; Nuño E; Godoy M; Prada JL; Olalla J; Aguilar J; Martos F;
    Enferm Infecc Microbiol Clin; 2008; 26(7):416-22. PubMed ID: 18842236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
    Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
    Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.
    d'Arminio Monforte A; Lepri AC; Rezza G; Pezzotti P; Antinori A; Phillips AN; Angarano G; Colangeli V; De Luca A; Ippolito G; Caggese L; Soscia F; Filice G; Gritti F; Narciso P; Tirelli U; Moroni M
    AIDS; 2000 Mar; 14(5):499-507. PubMed ID: 10780712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
    Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.
    Tremblay C; Trottier B; Rachlis A; Baril JG; Loutfy M; Lalonde R; Sampalis JS; Boulerice F
    HIV Clin Trials; 2011; 12(3):151-60. PubMed ID: 21684855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
    Jaspan HB; Berrisford AE; Boulle AM
    Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.
    Crane HM; Van Rompaey SE; Kitahata MM
    AIDS Patient Care STDS; 2007 Dec; 21(12):920-9. PubMed ID: 18154489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection.
    Klein MB; Willemot P; Murphy T; Lalonde RG
    AIDS; 2004 Sep; 18(14):1895-904. PubMed ID: 15353975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy.
    Willig JH; Abroms S; Westfall AO; Routman J; Adusumilli S; Varshney M; Allison J; Chatham A; Raper JL; Kaslow RA; Saag MS; Mugavero MJ
    AIDS; 2008 Oct; 22(15):1951-60. PubMed ID: 18784459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort.
    Dieleman JP; Jambroes M; Gyssens IC; Sturkenboom MC; Stricker BH; Mulder WM; de Wolf F; Weverling GJ; Lange JM; Reiss P; Brinkman K;
    AIDS; 2002 Mar; 16(5):737-45. PubMed ID: 11964530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses.
    Chou R; Fu R; Huffman LH; Korthuis PT
    Lancet; 2006 Oct; 368(9546):1503-15. PubMed ID: 17071284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.
    Palma P; Romiti ML; Cancrini C; Pensieroso S; Montesano C; Santucci MB; Bernardi S; Martino AM; Rossi P; Castelli-Gattinara G
    AIDS; 2007 Nov; 21(18):2465-72. PubMed ID: 18025883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy.
    Puthanakit T; Kerr S; Ananworanich J; Bunupuradah T; Boonrak P; Sirisanthana V
    Pediatr Infect Dis J; 2009 Jun; 28(6):488-92. PubMed ID: 19504731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection.
    Apuzzo LG; Vaida F; Gallant JE; Ernstrom KB; Little SJ; Routy JP; Collier AC; Conway B; Markowitz MH; Hecht FM; Walker BD; Connick E; Margolick JB
    J Acquir Immune Defic Syndr; 2009 Mar; 50(3):267-75. PubMed ID: 19194317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.